Search

Your search keyword '"Thibaudeau E"' showing total 116 results
Start Over Author "Thibaudeau E"
116 results on '"Thibaudeau E"'

4. Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study

Author

Ahrendt, S.A., Baik, S.H., Bhatt, A., Cachin, P., Ceelen, W., De Hingh, I., De Simone, M., Dubé, P., Edwards, R.P., Franko, J., Gonzalez-Bayon, L., Gushchin, V., Holtzman, M.P., Hsieh, M.-C., Kecmanovic, D., Lee, K.W., Lehmann, K., Levine, E.A., Liu, Y., Mehta, S., Morris, D.L., O'Dwyer, S., Orsenigo, E., Pande, P.K., Park, E.J., Pingpank, J.F., Piso, P., Rajan, F., Rau, B., Sardi, A., Sideris, L., Sommariva, A., Tentes, A.A.K., Teo, M., Yarema, R., Yonemura, Y., Younan, R., Zaveri, S.S., Zeh, H.J., Abba, J., Abboud, K., Alyami, M., Arvieux, C., Bakrin, N., Bereder, J.-M., Bouzard, D., Brigand, C., Carrère, S., Delroeux, D., Dumont, F., Eveno, C., Facy, O., Guyon, F., Ferron, G., Glehen, O., Kianmanesh, R., Lo Dico, R., Lorimier, G., Marchal, F., Mariani, P., Meeus, P., Msika, S., Ortega-Deballon, P., Paquette, B., Passot, G., Peyrat, P., Pirro, N., Pocard, M., Porcheron, J., Rat, P., Sgarbura, O., Thibaudeau, E., Tuech, J.-J., Zinzindohoue, F., Mehta, Sanket, Schwarz, Lilian, Spiliotis, John, Hsieh, Mao-Chih, Akaishi, Eduardo H., Goere, Diane, Sugarbaker, Paul H., Baratti, Dario, Quenet, François, Bartlett, David L., Villeneuve, Laurent, and Kepenekian, Vahan

Published
2018
Full Text
View/download PDF

8. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study

Author

Averous, G., Bereder, J.M., Bibeau, F., Bouzard, D., Chevallier, A., Croce, S., Dartigues, P., Durand-Fontanier, S., Gouthi, L., Heyd, B., Kaci, R., Kianmanesh, R., Laverrière, M.H., Leblanc, E., Lelong, B., Leroux, A., Loi, V., Mariette, C., Meeus, P., Msika, S., Pezet, D., Peyrat, P., Pirro, N., Paineau, J., Poizat, F., Porcheron, J., Quenet, F., Rat, P., Regimbeau, J.M., Thibaudeau, E., Tuech, J.J., Valmary-Degano, S., Verriele, V., Zerbib, P., Zinzindohoue, F., Kepenekian, V., Elias, D., Passot, G., Mery, E., Goere, D., Delroeux, D., Ferron, G., Guilloit, J.M., Pocard, M., Abboud, K., Arvieux, C., Brigand, C., Marchal, F., Classe, J.M., Lorimier, G., De Chaisemartin, C., Guyon, F., Mariani, P., Ortega-Deballon, P., Isaac, S., Maurice, C., Gilly, F.N., and Glehen, O.

Published
2016
Full Text
View/download PDF

18. Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study

Author

Mehta, Sanket, primary, Schwarz, Lilian, additional, Spiliotis, John, additional, Hsieh, Mao-Chih, additional, Akaishi, Eduardo H., additional, Goere, Diane, additional, Sugarbaker, Paul H., additional, Baratti, Dario, additional, Quenet, François, additional, Bartlett, David L., additional, Villeneuve, Laurent, additional, Kepenekian, Vahan, additional, Ahrendt, S.A., additional, Baik, S.H., additional, Bhatt, A., additional, Cachin, P., additional, Ceelen, W., additional, De Hingh, I., additional, De Simone, M., additional, Dubé, P., additional, Edwards, R.P., additional, Franko, J., additional, Gonzalez-Bayon, L., additional, Gushchin, V., additional, Holtzman, M.P., additional, Hsieh, M.-C., additional, Kecmanovic, D., additional, Lee, K.W., additional, Lehmann, K., additional, Levine, E.A., additional, Liu, Y., additional, Mehta, S., additional, Morris, D.L., additional, O'Dwyer, S., additional, Orsenigo, E., additional, Pande, P.K., additional, Park, E.J., additional, Pingpank, J.F., additional, Piso, P., additional, Rajan, F., additional, Rau, B., additional, Sardi, A., additional, Sideris, L., additional, Sommariva, A., additional, Tentes, A.A.K., additional, Teo, M., additional, Yarema, R., additional, Yonemura, Y., additional, Younan, R., additional, Zaveri, S.S., additional, Zeh, H.J., additional, Abba, J., additional, Abboud, K., additional, Alyami, M., additional, Arvieux, C., additional, Bakrin, N., additional, Bereder, J.-M., additional, Bouzard, D., additional, Brigand, C., additional, Carrère, S., additional, Delroeux, D., additional, Dumont, F., additional, Eveno, C., additional, Facy, O., additional, Guyon, F., additional, Ferron, G., additional, Glehen, O., additional, Kianmanesh, R., additional, Lo Dico, R., additional, Lorimier, G., additional, Marchal, F., additional, Mariani, P., additional, Meeus, P., additional, Msika, S., additional, Ortega-Deballon, P., additional, Paquette, B., additional, Passot, G., additional, Peyrat, P., additional, Pirro, N., additional, Pocard, M., additional, Porcheron, J., additional, Rat, P., additional, Sgarbura, O., additional, Thibaudeau, E., additional, Tuech, J.-J., additional, and Zinzindohoue, F., additional

Published
2018
Full Text
View/download PDF

20. Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups

Author

Amblard, I., primary, Mercier, F., additional, Bartlett, D.L., additional, Ahrendt, S.A., additional, Lee, K.W., additional, Zeh, H.J., additional, Levine, E.A., additional, Baratti, D., additional, Deraco, M., additional, Piso, P., additional, Morris, D.L., additional, Rau, B., additional, Tentes, A.A.K., additional, Tuech, J.-J., additional, Quenet, F., additional, Akaishi, E., additional, Pocard, M., additional, Yonemura, Y., additional, Lorimier, G., additional, Delroeux, D., additional, Villeneuve, L., additional, Glehen, O., additional, Passot, G., additional, Abba, J., additional, Abboud, K., additional, Alyami, M., additional, Arvieux, C., additional, Bakrin, N., additional, Bereder, J.-M., additional, Bouzard, D., additional, Brigand, C., additional, Carrère, S., additional, Dumont, F., additional, Eveno, C., additional, Facy, O., additional, Guyon, F., additional, Kianmanesh, R., additional, Lo Dico, R., additional, Marchal, F., additional, Mariani, P., additional, Meeus, P., additional, Msika, S., additional, Ortega-Deballon, P., additional, Paquette, B., additional, Peyrat, P., additional, Pirro, N., additional, Porcheron, J., additional, Rat, P., additional, Sgarbura, O., additional, Thibaudeau, E., additional, Zinzindohoue, F., additional, Baik, S.H., additional, Bhatt, A., additional, Cachin, P., additional, Ceelen, W., additional, De Hingh, I., additional, De Simone, M., additional, Dubé, P., additional, Edwards, R.P., additional, Franko, J., additional, Gonzalez-Bayon, L., additional, Gushchin, V., additional, Holtzman, M.P., additional, Hsieh, M.-C., additional, Kecmanovic, D., additional, Lehmann, K., additional, Liu, Y., additional, Mehta, S., additional, O'Dwyer, S., additional, Orsevigo, E., additional, Pande, P.K., additional, Park, E.J., additional, Pingpank, J.F., additional, Rajan, F., additional, Sardi, A., additional, Sideris, L., additional, Sommariva, A., additional, Spiliotis, J., additional, Sugarbaker, P., additional, Teo, M., additional, Yarema, R., additional, Younan, R., additional, and Zaveri, S.S., additional

Published
2018
Full Text
View/download PDF

22. Multicentre study of laparoscopic or open assessment of the peritoneal cancer index (BIG-RENAPE)

Author

Passot, G, primary, Dumont, F, additional, Goéré, D, additional, Arvieux, C, additional, Rousset, P, additional, Regimbeau, J-M, additional, Elias, D, additional, Villeneuve, L, additional, Glehen, O, additional, Abba, J, additional, Abboud, K, additional, Carere, S, additional, Durand-Fontanier, S, additional, Eveno, C, additional, Facy, O, additional, Gelli, M, additional, Gilly, F-N, additional, Karoui, M, additional, Lo Dico, R, additional, Ortega-Deballon, P, additional, Pocard, M, additional, Quenet, F, additional, Rat, P, additional, Sabbagh, C, additional, Sgarbura, O, additional, Thibaudeau, E, additional, Vaudoyer, D, additional, and Wernert, R, additional

Published
2018
Full Text
View/download PDF

23. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin

Author

Delhorme, J-B, primary, Severac, F, additional, Averous, G, additional, Glehen, O, additional, Passot, G, additional, Bakrin, N, additional, Marchal, F, additional, Pocard, M, additional, Lo Dico, R, additional, Eveno, C, additional, Carrere, S, additional, Sgarbura, O, additional, Quenet, F, additional, Ferron, G, additional, Goéré, D, additional, Brigand, C, additional, Abba, J, additional, Abboud, K, additional, Alyami, M, additional, Arvieux, C, additional, Balagué, G, additional, Barrau, V, additional, Ben Rejeb, H, additional, Bereder, J-M, additional, Berton-Rigaud, I, additional, Bibeau, F, additional, Bonnefoy, I, additional, Bouzard, D, additional, Bricault, I, additional, Carrère, S, additional, de Chaisemartin, C, additional, Chassang, M, additional, Chevallier, A, additional, Courvoisier, T, additional, Dartigues, P, additional, Dohan, A, additional, Dubreuil, J, additional, Dumont, F, additional, Faruch-Bilfeld, M, additional, Fontaine, J, additional, Fournier, L, additional, Gagniere, J, additional, Geffroy, D, additional, Ghouti, L, additional, Gilly, F-N, additional, Gladieff, L, additional, Guibal, A, additional, Guilloit, J-M, additional, Guyon, F, additional, Heyd, B, additional, Hoeffel, C, additional, Hordonneau, C, additional, Isaac, S, additional, Jourdan-Enfer, P, additional, Kaci, R, additional, Kianmanesh, R, additional, Labbé-Devilliers, C, additional, Lacroix, J, additional, Lelong, B, additional, Leroux-Broussier, A, additional, Lherm, Y, additional, Lorimier, G, additional, Malhaire, C, additional, Mariani, P, additional, Mathiotte, E, additional, Meeus, P, additional, Mery, E, additional, Msika, S, additional, Nadeau, C, additional, Ortega-Deballon, P, additional, Pellet, O, additional, Peyrat, P, additional, Pezet, D, additional, Pirro, N, additional, Poizat, F, additional, Porcheron, J, additional, Poulet, A, additional, Rat, P, additional, Rousselot, P, additional, Rousset, P, additional, Senellart, H, additional, Serrano, M, additional, Servois, V, additional, Sgabura, O, additional, Skanjeti, A, additional, Svrcek, M, additional, Tetreau, R, additional, Thibaudeau, E, additional, Touchefeu, Y, additional, Tuech, J-J, additional, Valmary-Degano, S, additional, Vaudoyer, D, additional, Velasco, S, additional, Verriele-Beurrier, V, additional, Villeneuve, L, additional, Wernert, R, additional, and Zinzindohoue, F, additional

Published
2018
Full Text
View/download PDF

24. Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study

Author

Valmary-Degano, S., primary, Colpart, P., additional, Villeneuve, L., additional, Monnien, F., additional, M'Hamdi, L., additional, Lang Averous, G., additional, Capovilla, M., additional, Bibeau, F., additional, Laverriere, M.-H., additional, Verriele-Beurrier, V., additional, Ben Rejeb, H., additional, Dartigues, P., additional, Hommell-Fontaine, J., additional, Gilly, F.-N., additional, Isaac, S., additional, Mery, E., additional, Abba, J., additional, Abboud, K., additional, Alyami, M., additional, Arvieux, C., additional, Bakrin, N., additional, Balagué, G., additional, Barrau, V., additional, Bereder, J.-M., additional, Berton-Rigaud, I., additional, Bonnefoy, I., additional, Bouzard, D., additional, Bricault, I., additional, Brigand, C., additional, Carrère, S., additional, de Chaisemartin, C., additional, Chassang, M., additional, Chevallier, A., additional, Courvoisier, T., additional, Dohan, A., additional, Dromain, C., additional, Dubreuil, J., additional, Dumont, F., additional, Eveno, C., additional, Faruch-Bilfeld, M., additional, Ferron, G., additional, Fournier, L., additional, Gagniere, J., additional, Geffroy, D., additional, Ghouti, L., additional, Gladieff, L., additional, Glehen, O., additional, Goéré, D., additional, Guibal, A., additional, Guilloit, J.-M., additional, Guyon, F., additional, Heyd, B., additional, Hoeffel, C., additional, Hordonneau, C., additional, Jourdan-Enfer, P., additional, Kaci, R., additional, Kianmanesh, R., additional, Labbé-Devilliers, C., additional, Lacroix, J., additional, Lelong, B., additional, Leroux-Broussier, A., additional, Lherm, Y., additional, Lo Dico, R., additional, Lorimier, G., additional, Malhaire, C., additional, Marchal, F., additional, Mariani, P., additional, Mathiotte, E., additional, Meeus, P., additional, Msika, S., additional, Nadeau, C., additional, Ortega-Deballon, P., additional, Passot, G., additional, Pellet, O., additional, Peyrat, P., additional, Pezet, D., additional, Pirro, N., additional, Pocard, M., additional, Poizat, F., additional, Porcheron, J., additional, Poulet, A., additional, Quenet, F., additional, Rat, P., additional, Rousselot, P., additional, Senellart, H., additional, Serrano, M., additional, Servois, V., additional, Sgabura, O., additional, Skanjeti, A., additional, Svrcek, M., additional, Tetreau, R., additional, Thibaudeau, E., additional, Touchefeu, Y., additional, Tuech, J.-J., additional, Vaudoyer, D., additional, Velasco, S., additional, Wernert, R., additional, and Zinzindohoue, F., additional

Published
2017
Full Text
View/download PDF

26. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database

Author

Kepenekian, V., primary, Elias, D., additional, Passot, G., additional, Mery, E., additional, Goere, D., additional, Delroeux, D., additional, Quenet, F., additional, Ferron, G., additional, Pezet, D., additional, Guilloit, J.M., additional, Meeus, P., additional, Pocard, M., additional, Bereder, J.M., additional, Abboud, K., additional, Arvieux, C., additional, Brigand, C., additional, Marchal, F., additional, Classe, J.M., additional, Lorimier, G., additional, De Chaisemartin, C., additional, Guyon, F., additional, Mariani, P., additional, Ortega-Deballon, P., additional, Isaac, S., additional, Maurice, C., additional, Gilly, F.N., additional, Glehen, O., additional, Averous, G., additional, Bibeau, F., additional, Bouzard, D., additional, Chevallier, A., additional, Croce, S., additional, Dartigues, P., additional, Durand-Fontanier, S., additional, Gouthi, L., additional, Heyd, B., additional, Kaci, R., additional, Kianmanesh, R., additional, Laverrière, M.H., additional, Leblanc, E., additional, Lelong, B., additional, Leroux, A., additional, Loi, V., additional, Mariette, C., additional, Msika, S., additional, Peyrat, P., additional, Pirro, N., additional, Paineau, J., additional, Poizat, F., additional, Porcheron, J., additional, Rat, P., additional, Regimbeau, J.M., additional, Thibaudeau, E., additional, Tuech, J.J., additional, Valmary-Degano, S., additional, Verriele, V., additional, Zerbib, P., additional, and Zinzindohoue, F., additional

Published
2016
Full Text
View/download PDF

27. A new internet tool to report peritoneal malignancy extent. PeRitOneal MalIgnancy Stage Evaluation (PROMISE) application

Author

Villeneuve, L., primary, Thivolet, A., additional, Bakrin, N., additional, Mohamed, F., additional, Isaac, S., additional, Valette, P.-J., additional, Glehen, O., additional, Rousset, P., additional, Abba, J., additional, Abboud, K., additional, Arvieux, C., additional, Balagué, G., additional, Barrau, V., additional, Rejeb, H.B., additional, Bereder, J.-M., additional, Bibeau, F., additional, Bouzard, D., additional, Brigand, C., additional, Carrère, S., additional, Carretier, M., additional, de Chaisemartin, C., additional, Chassang, M., additional, Chevallier, A., additional, Courvoisier, T., additional, Dartigues, P., additional, Delroeux, D., additional, Desolneux, G., additional, Dohan, A., additional, Dromain, C., additional, Dumont, F., additional, Durand-Fontanier, S., additional, Elias, D., additional, Eveno, C., additional, Evrard, S., additional, Fay, O., additional, Ferron, G., additional, Geffroy, D., additional, Gilly, F.-N., additional, Fontaine, J., additional, Goasguen, N., additional, Ghouti, L., additional, Goéré, D., additional, Guilloit, J.-M., additional, Guyon, F., additional, Heyd, B., additional, Kaci, R., additional, Karoui, M., additional, Kianmanesh, R., additional, Labbé, C., additional, Lacroix, J., additional, Lang-Averous, G., additional, Laverriere, M.-H., additional, Lefevre, J., additional, Lelong, B., additional, Leroux, A., additional, Dico, R.L., additional, Loi, V., additional, Lorimier, G., additional, Marchal, F., additional, Mariani, A., additional, Mariani, P., additional, Mariette, C., additional, Meeus, P., additional, Mery, E., additional, Messager, M., additional, Msika, S., additional, Nadeau, C., additional, Ortega-Deballon, P., additional, Passot, G., additional, Petorin, C., additional, Peyrat, P., additional, Pezet, D., additional, Piessen, G., additional, Pirro, N., additional, Pocard, M., additional, Poizat, F., additional, Porcheron, J., additional, Pourcher, G., additional, Quenet, F., additional, Rat, P., additional, Regimbeau, J.-M., additional, Rousselot, P., additional, Sabbagh, C., additional, Svrcek, M., additional, Tetreau, R., additional, Thibaudeau, E., additional, Tuech, J.-J., additional, Valmary-Degano, S., additional, Vaudoyer, D., additional, Velasco, S., additional, Verriele-Beurrier, V., additional, Wernert, R., additional, and Zinzindohoue, F., additional

Published
2016
Full Text
View/download PDF

29. Acute respiratory distress syndrome (ARDS) after pressurized intraperitoneal aerosol chemotherapy with oxaliplatin: a case report

Author

Thibaudeau Emilie, Brianchon Corinne, Raoul Jean-Luc, and Dumont Frédéric

Subjects
acute respiratory distress syndrome, complications, oxaliplatin, peritoneal carcinomatosis, pipac, Medicine, Specialties of internal medicine, RC581-951
Abstract

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new drug delivery method for intraabdominal cavity chemotherapy. It combines the benefits of a minimally invasive approach (low morbidity and easy to repeat) with the pharmacokinetic advantages of intraperitoneal administration and tolerance seems excellent. We would like to report one case of a serious adverse event, acute respiratory distress syndrome, which is likely related to oxaliplatin administration; all signs disappeared within a few days.

Published
2021
Full Text
View/download PDF

30. Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): A French multicentric survey

Author

Ferron, G., primary, Simon, L., additional, Guyon, F., additional, Glehen, O., additional, Goere, D., additional, Elias, D., additional, Pocard, M., additional, Gladieff, L., additional, Bereder, J.M., additional, Brigand, C., additional, Classe, J.M., additional, Guilloit, J.M., additional, Quenet, F., additional, Abboud, K., additional, Arvieux, C., additional, Bibeau, F., additional, De Chaisemartin, C., additional, Delroeux, D., additional, Durand-Fontanier, S., additional, Goasguen, N., additional, Gouthi, L., additional, Heyd, B., additional, Kianmanesh, R., additional, Leblanc, E., additional, Loi, V., additional, Lorimier, G., additional, Marchal, F., additional, Mariani, P., additional, Mariette, C., additional, Meeus, P., additional, Msika, S., additional, Ortega-Deballon, P., additional, Paineau, J., additional, Pezet, D., additional, Piessen, G., additional, Pirro, N., additional, Pomel, C., additional, Porcheron, J., additional, Pourcher, G., additional, Rat, P., additional, Regimbeau, J.M., additional, Sabbagh, C., additional, Thibaudeau, E., additional, Torrent, J.J., additional, Tougeron, D., additional, Tuech, J.J., additional, Zinzindohoue, F., additional, Lundberg, P., additional, Herin, F., additional, and Villeneuve, L., additional

Published
2015
Full Text
View/download PDF

33. Development of a reporter gene assay for both Gs and Gqcoupled prostanoid receptors stably expressed in HEK293 EBNA

Author

Durocher, Y., Perret, S., Thibaudeau, E., Gaumond, M. H., Kamen, A., Stocco, R., and Abramovitz, M.

Subjects
health care facilities, manpower, and services, education, lipids (amino acids, peptides, and proteins), health care economics and organizations, biotechnology
Abstract

The 11 International Conference on advances in prostaglandin and leukotriene research, Florence, Italy, June 2000

Published
2009

40. Colostomías

Author

Thibaudeau, E., primary, Brachet, D., additional, Vénara, A., additional, and Arnaud, J.-P., additional

Published
2012
Full Text
View/download PDF

41. HPV prevalence and prognostic value in a prospective cohort of 255 patients with locally advanced squamous cell carcinoma of the head and neck treated with chemoradiation therapy at Centre Hospitalier de l'Université de Montréal: A single-center experience.

Author

Thibaudeau, E., primary, Soulieres, D., additional, Fortin, B., additional, Coutlee, F., additional, Nguyen-Tan, P., additional, Weng, X., additional, Audette, M., additional, Abboud, O., additional, Guertin, L., additional, Christopoulos, A., additional, and Tabet, J., additional

Published
2011
Full Text
View/download PDF

43. PIPAC in patients with peritoneal metastases from gastrointestinal tract (PIPOX01): An open label, non-comparative phase 1/2 dose escalation and expansion trial.

Author

Dumont F, Kepenekian V, Passot C, Ezanno-Manasterski AC, Pocard M, Raoul JL, Lelièvre B, Hiret S, Senellart H, Pein F, Raimbourg J, Campion L, Thibaudeau E, Paul J, and Glehen O

Subjects
Humans, Male, Middle Aged, Female, Aged, Adult, Aerosols, Stomach Neoplasms pathology, Stomach Neoplasms drug therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colorectal Neoplasms pathology, Colorectal Neoplasms drug therapy, Peritoneal Neoplasms secondary, Peritoneal Neoplasms drug therapy, Oxaliplatin administration & dosage, Gastrointestinal Neoplasms pathology, Gastrointestinal Neoplasms drug therapy
Abstract

Background: Despite modern systemic chemotherapy, survival remains poor for patients with advanced isolated peritoneal metastases from the gastrointestinal tract. We aimed to assess the safety and efficacy of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin., Patients and Methods: We conducted a phase 1/2, open label, non-comparative, dose escalation and expansion trial of PIPAC with oxaliplatin in patients with a peritoneal cancer index (PCI) of more than 5, 13 and 15 for respectively a gastric, small bowel and colorectal primary cancer, and who had received at least three months of systemic chemotherapy. PIPAC cycle lengths were 4-6 weeks with systemic chemotherapy allowed 15 days after each PIPAC. PCI and oxaliplatin tumor concentration were assessed every PIPAC cycle. The main endpoints were tolerability, tumor response, and survival., Results: Between 2017 and 2020, 34 patients were enrolled in three centers, in this phase 1/2 study, of whom 25 were evaluable at the recommended dose determined in the phase I trial (90 mg/m 2 plus systemic 5-FU). Before inclusion, patients received a median of 2 [1-4] chemotherapy lines and had a median PCI of 22.5 [7-29]. At this dose, the safety profile showed acceptable tolerability. Eight patients (32 %) had grade 3/4 treatment-related adverse events. Minor (grade 1/2) adverse events were mainly abdominal pain (n = 19, 76 %) and nausea (n = 16, 64 %). Median PFS was 6.1 months and median OS was 13 months., Conclusion: In patients with advanced and refractory peritoneal metastasis, PFS of 6.1 months is encouraging. A prospective randomized phase II study is required., (Copyright © 2024 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.)

Published
2024
Full Text
View/download PDF

44. Assessing the fidelity of supported education programs for first-episode psychosis to the supported employment guidelines adapted for education.

Author

Thibaudeau E, Lecomte T, Corbière M, Abdel-Baki A, Simard A, Roy MA, and Cellard C

Abstract

Introduction: Psychotic disorders are associated with academic difficulties. Supported Employment Program (SEP) guidelines have become the gold standard to improve occupational functioning in psychotic disorders. More recently, these guidelines have been adapted to education. In Canada, several community organizations and hospital programs offer supported education to young people with psychotic disorders. However, SEP guidelines are not systematically used. The objective of this study was to assess the fidelity of 6 Canadian (Quebec) organizations offering supported education services to young people with psychotic disorders to the SEP guidelines adapted to education., Methods: Six sites offering educational services to young people with psychotic disorders were recruited. Semi-structured interviews were conducted with one supported education professional and one manager of each site, using the Quality of Supported Education Implementation Scale (QSEDIS). This new scale has been developed from the Quality of Supported Employment Implementation Scale. The QSEDIS assesses the fidelity of the quality of the implementation of supported education programs, using three subscales (Employees, Organization and Services)., Results: Acceptable fidelity scores were observed in the three QSEDIS subscales for all six sites combined. The Services subscale received the highest score of fidelity (4.4/5), followed by the Supported Education Employee (4.1/5) and the Organization (3.7/5)., Conclusion: The results suggest that supported education services offered to young people with psychotic disorders in the six sites are generally consistent with SEP guidelines adapted to education. Further research is warranted to validate whether acceptable SEP guidelines fidelity according to the QSEDIS translates into educational outcomes., (© 2024 The Authors. Early Intervention in Psychiatry published by John Wiley & Sons Australia, Ltd.)

Published
2024
Full Text
View/download PDF

45. Navigating Social Cognitive Impairments in Schizophrenia Spectrum Disorders: Protocol for a Pilot Pre-Post Quasi-Experimental Study for Remote Avatar-Assisted Cognitive Remediation Therapy.

Author

Thibaudeau E, Peyroux E, Franck N, Carling H, and Lepage M

Abstract

Background: Social cognitive impairments are prevalent in schizophrenia spectrum disorder (SSD) and have detrimental effects on functioning. Cognitive remediation (CR) has shown its efficacy in improving social cognitive impairments, although the transfer of these skills to daily life and the personalization of these interventions remain challenging. RC2S (Remédiation Cognitive de la Cognition Sociale dans la Schizophrénie; Cognitive remediation of social cognition in Schizophrenia) is a French CR that combines the learning of strategies and practice using paper-and-pencil exercises and digital relational simulations. This French program was designed as an in-person intervention., Objective: This project aims to culturally adapt the RC2S program, in French-Canadian and North American English and to assess the feasibility, acceptability, safety, and implementation of a remote version in people with SSD. An exploratory objective is to assess the preliminary effect of remote RC2S on goal attainment, social cognition, and psychosocial outcomes., Methods: We will use a pre-post quasi-experimental design. First, the translation and cultural adaptation in North American English and French-Canadian of RC2S is presented. Then, 20 participants aged ≥18 years with a diagnosis of SSD, presenting with a subjective or an objective impairment in social cognition, will be included to receive RC2S. In addition, 5 therapists will be included as research participants to assess their perspective on RC2S. Participants with SSD will undergo a baseline remote assessment of their social cognition, clinical symptoms, and functioning. They will then start remote RC2S for 24 biweekly individual 1-hour sessions with a therapist. Following the case formulation and goal setting, participants will complete personalized paper-and-pencil exercises to develop strategies and integrative digital relational simulations, during which they will help an avatar navigate through a variety of social contexts and relationships. The last 2 sessions are dedicated to the transfer to daily life. All participants will complete in-session questionnaires assessing therapeutic alliance, motivation, acceptability, feasibility, and implementation. Following RC2S, the participants with SSD will repeat the same assessment as the baseline. Descriptive statistics will be used to summarize the data about acceptability, feasibility, safety, and implementation. To assess the preliminary effect of RC2S, an intention-to-treat approach will be used with linear mixed models for repeated measures with fixed effects of time., Results: So far, 45% (9/20) of participants with SSD (mean age 37.9, SD 9.3 years) have completed the project. They received a mean of 20.5 out of 24 (SD 3.5) sessions of RC2S. A total of 5 therapists also completed the project., Conclusions: Improving social cognitive impairments is an important target in SSD to promote functional recovery. Using digital technologies to address these impairments and deliver the intervention is a promising approach to increase the ecological validity of CR and access to the intervention., Trial Registration: ClinicalTrials.gov NCT05017532; https://classic.clinicaltrials.gov/ct2/show/NCT05017532., International Registered Report Identifier (irrid): DERR1-10.2196/54251., (©Elisabeth Thibaudeau, Elodie Peyroux, Nicolas Franck, Hannah Carling, Martin Lepage. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 13.03.2024.)

Published
2024
Full Text
View/download PDF

46. Disentangling the Relationships Between the Clinical Symptoms of Schizophrenia Spectrum Disorders and Theory of Mind: A Meta-analysis.

Author

Thibaudeau E, Rae J, Raucher-Chéné D, Bougeard A, and Lepage M

Subjects
Humans, Cognition, Thinking, Schizophrenic Psychology, Schizophrenia diagnosis, Theory of Mind
Abstract

Background and Hypothesis: Previous studies have suggested links between clinical symptoms and theory of mind (ToM) impairments in schizophrenia spectrum disorders (SSD), but it remains unclear whether some symptoms are more strongly linked to ToM than others., Study Design: A meta-analysis (Prospero; CRD42021259723) was conducted to quantify and compare the strength of the associations between ToM and the clinical symptoms of SSD (Positive, Negative, Cognitive/Disorganization, Depression/Anxiety, Excitability/Hostility). Studies (N = 130, 137 samples) including people with SSD and reporting a correlation between clinical symptoms and ToM were retrieved from Pubmed, PsycNet, Embase, Cochrane Library, Science Direct, Proquest, WorldCat, and Open Gray. Correlations for each dimension and each symptom were entered into a random-effect model using a Fisher's r-to-z transformation and were compared using focused-tests. Publication bias was assessed with the Rosenthal failsafe and by inspecting the funnel plot and the standardized residual histogram., Study Results: The Cognitive/Disorganization (Zr = 0.28) and Negative (Zr = 0.24) dimensions revealed a small to moderate association with ToM, which was significantly stronger than the other dimensions. Within the Cognitive/Disorganization dimension, Difficulty in abstract thinking (Zr = 0.36) and Conceptual disorganization (Zr = 0.39) showed the strongest associations with ToM. The association with the Positive dimension (Zr = 0.16) was small and significantly stronger than the relationship with Depression/Anxiety (Zr = 0.09). Stronger associations were observed between ToM and clinical symptoms in younger patients, those with an earlier age at onset of illness and for tasks assessing a combination of different mental states., Conclusions: The relationships between Cognitive/Disorganization, Negative symptoms, and ToM should be considered in treating individuals with SSD., (© The Author(s) 2022. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2023
Full Text
View/download PDF

47. Surgery of resectable local recurrence following colorectal cancer: Compartmental surgery improves local control.

Author

Dumont F, Loaec C, Wernert R, Maurel B, Thibaudeau E, and Vilcot L

Subjects
Humans, Neoplasm Recurrence, Local pathology, Prognosis, Proportional Hazards Models, Retrospective Studies, Survival Rate, Colorectal Neoplasms pathology, Digestive System Surgical Procedures
Abstract

Background: This study aims to identify prognostic factors and define the best extent of surgery for optimizing treatment of local recurrence (LR) following colorectal cancer (CRC)., Methods: An institutional database of consecutive patients who underwent radical resection (R0/R1) of LR following CRC was analyzed prospectively from 2010 to 2021 at one tertiary cancer center., Results: In this study, 75 patients were included with LR following CRC and analyzed. Patients were categorized as compartmental resections (CompRe) (n = 47) if all adjacent organs were systematically removed, with or without tumor involvement, or noncompartmental resections (NoCompRe) (n = 28) if only contiguously involved organs were resected. NoCompRe were mainly related to contact between major vessels or bone and the tumor, with only 8/19 (42.1%) resections. Five-year overall survival and locoregional-free survival were 37.5% and 38.8% respectively. Local control was better in the CompRe than the NocompRe group (61.4% vs. 11%; p < 0.01). CompRe (hazard ratio: 2.34 [1.16-4.68]; p = 0.017) and absence of peritoneal metastasis (3.05 [1.03-9.02]; p = 0.044) were the two factors associated with decreased abdominal recurrences in multivariate analysis., Conclusion: Complete compartmental surgery is safe and improves local control. Optimal LR resection needs to remove all contiguous organs, with or without tumor involvement., (© 2022 Wiley Periodicals LLC.)

Published
2022
Full Text
View/download PDF

48. Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study.

Author

Taibi A, Sgarbura O, Hübner M, Bardet SM, Alyami M, Bakrin N, Durand Fontanier S, Eveno C, Gagniere J, Pache B, Pocard M, Quenet F, Teixeira Farinha H, Thibaudeau E, Dumont F, and Glehen O

Subjects
Aerosols, Cohort Studies, Feasibility Studies, Fluorouracil therapeutic use, Humans, Leucovorin therapeutic use, Oxaliplatin, Colorectal Neoplasms drug therapy, Colorectal Neoplasms pathology, Peritoneal Neoplasms secondary
Abstract

Background: This retrospective multicenter cohort study compared the feasibility and safety of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC-Ox) with or without intraoperative intravenous 5-fluorouracil (5-FU) and leucovorin (L)., Methods: Our study included consecutive patients with histologically proven unresectable and isolated colorectal peritoneal metastases (cPM) treated with PIPAC-Ox in seven tertiary referral centers between January 2015 and April 2020. Toxicity events and oncological outcomes (histological response, progression-free survival, and overall survival) were compared between patients who received intraoperative intravenous 5-FU/L (PIPAC-Ox + 5-FU/L group) and patients who did not (PIPAC-Ox group)., Results: In total, 101 patients (263 procedures) were included in the PIPAC-Ox group and 30 patients (80 procedures) were included in the PIPAC-Ox + 5-FU/L group. Common Terminology Criteria for Adverse Events v4.0 grade 2 or higher adverse events occurred in 48 of 101 (47.5%) patients in the PIPAC-Ox group and in 13 of 30 (43.3%) patients in the PIPAC-Ox + 5-FU/L group (p = 0.73). The complete histological response rates according to the peritoneal regression grading score were 27% for the PIPAC-Ox + 5-FU/L group and 18% for the PIPAC-Ox group (p = 0.74). No statistically significant differences were observed in overall or progression-free survival between the two groups., Conclusions: The safety and feasibility of PIPAC-Ox + 5-FU/L appears to be similar to the safety and feasibility of PIPAC-Ox alone in patients with unresectable cPM. Oncological outcomes must be evaluated in larger studies., (© 2022. Society of Surgical Oncology.)

Published
2022
Full Text
View/download PDF

49. Survival after cytoreductive surgery for peritoneal metastases in colorectal cancer patients: Does a history of resected liver metastases worsen the prognosis?

Author

Dumont F, Guénolé S, Loaec C, Bourgin C, Raimbourg J, Senellart H, Hiret S, Doucet L, Raoul JL, and Thibaudeau E

Subjects
Combined Modality Therapy, Cytoreduction Surgical Procedures, Humans, Peritoneum pathology, Prognosis, Retrospective Studies, Survival Rate, Carcinoma, Signet Ring Cell, Colorectal Neoplasms pathology, Hyperthermia, Induced, Liver Neoplasms secondary, Peritoneal Neoplasms secondary
Abstract

Background: Nowadays, resection of two (liver and peritoneum) concomitant colorectal cancer metastatic sites is no longer contraindicated. However, the oncologic outcomes of resecting peritoneal metastases (PM) occurring more than six months after resection of liver metastases (LM) are unknown., Aim: The aim of this study was to compare patients with complete cytoreductive surgery (CRS) with or without a history of previous liver resection (LR)., Methods: Analysis from a prospective database of 74 patients with metachronous PM treated with CRS between 2010 and 2020., Results: All patients had PM metachronous to primary, 64 patients underwent CRS alone (CRSa) and 10 CRS more than six months after LR (LR-CRS). There was no statistical difference between the groups for clinical or therapeutic characteristics. There were more signet ring cell/mucinous adenocarcinomas in the CRSa group than in the LR-CRS group (19% vs. 0%, p = 0.049). The median peritoneal cancer index (PCI) was 4 and 6 (p = 0.749) in the LR-CRS and CRSa groups, respectively. Median overall survival (OS) and disease-free survival (DFS) were not statistically different between the two groups with 43.6 and 13 months for the CRSa group and 31.1 months and 9.4 months for LR-CRS. Advanced age was an independent negative prognostic factor for OS and high PCI was limit significant. No prognostic factor for DFS was found., Conclusions: LR before CRS has no major prognostic impact. Resection of iterative liver and peritoneum metastases can achieve long-term survival., Competing Interests: Declaration of competing interest No funding or other financial support was received for this work. The authors declare no potential conflict of interest with reference to this article., (Copyright © 2021 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.)

Published
2022
Full Text
View/download PDF

50. Understanding others as a mediator between verbal memory and negative symptoms in schizophrenia-spectrum disorder.

Author

Raucher-Chéné D, Thibaudeau E, Sauvé G, Lavigne KM, and Lepage M

Subjects
Cognition, Humans, Memory, Neuropsychological Tests, Cognition Disorders, Cognitive Dysfunction, Psychotic Disorders complications, Schizophrenia complications, Theory of Mind
Abstract

From the onset of schizophrenia, verbal memory (VM) deficits and negative symptoms are strongly associated, and both additively predict functional outcomes. Emotion recognition (ER) and theory of mind (ToM; the ability to infer others' mental states), two components of social cognition, are also particularly affected in schizophrenia. Explanatory models of negative symptoms have integrated these cognitive impairments as potential precursors and previous studies revealed relationships between ER and/or ToM and VM, as well as with negative symptoms, but the organization of these associations remains unclear. We aimed to determine whether impairments in VM and social cognition sequentially pave the way for negative symptoms in schizophrenia. To this end, we used mediation analyses. One hundred and forty participants with a diagnosis of schizophrenia or schizoaffective disorder were recruited. First, correlational analyses were conducted between our variables of interest. The mediating effect of social cognition between VM and negative symptoms was then examined using the PROCESS macro. Variables of interest were significantly correlated (r = |0.166| to |0.391|), except for ER and negative symptoms. Only the serial multiple mediation model with 2 mediators (ER followed by ToM) revealed a significant indirect effect of VM on negative symptoms (β = - 0.160, 95% CI = -.370 to -.004). This relationship was selective for expressive negative symptoms (e.g., blunted affect and alogia). This study illustrates the richness of the relationship between cognitive deficits and negative symptoms and provides additional information for the involvement of social cognition in negative symptoms' etiology., (Copyright © 2021 Elsevier Ltd. All rights reserved.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results